Access count of this item: 0

Files in This Item:
This article will be available after a certain embargo period.
Please see the "Rights" information in item metadata display about embargo date.
Title: Evaluation of [¹⁸F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide function
Authors: Yagi, Yusuke
Kimura, Hiroyuki
Okuda, Haruka
Ono, Masahiro
Nakamoto, Yuji
Togashi, Kaori
Saji, Hideo
Author's alias: 屋木, 祐亮
木村, 寛之
小野, 正博 /中本, 裕士
富樫, かおり
佐治, 英郎
Keywords: Organic anion transporting polypeptide
Positron-emission tomography
Fluorine-18
Pitavastatin
Integration plot method
Issue Date: Jul-2019
Publisher: Elsevier Inc.
Journal title: Nuclear Medicine and Biology
Volume: 74-75
Start page: 25
End page: 31
Abstract: Introduction: To understand the pathways involved in drug clearance from the body, quantitative evaluations of the hepatobiliary transport of drugs are important. The organic anion transporting polypeptide (OATP) family transporter, particularly OATP1B1 and 1B3, are considered to play an important role in hepatic uptake of organic anion compounds. Pitavastatin is a substrate of OATP, and it includes a fluorine group. Therefore, it represents an acceptable positron-emission tomography (PET) tracer using fluorine-18 to image in vivo hepatic transporter functions. Method: [¹⁸F]Pitavastatin was synthesized using the method we previously reported. To evaluate the potential of [¹⁸F]pitavastatin in PET imaging of in vivo OATP functions, we investigated the hepatic uptake with/without rifampicin as an OATP inhibitor after administration in normal SD rats. [¹⁸F]Pitavastatin metabolite was evaluated using reverse-phase thin-layer chromatography (TLC) autoradiography. We subsequently analyzed the PET image results and demonstrated that [¹⁸F]pitavastatin selectively accumulated in the liver post-administration. Result and discussion: In metabolite analysis using reverse-phase TLC, we found that the radioactivity detected in the plasma, liver (>90% intact), and bile mostly originated from the parent pitavastatin of the PET study (~40 min). [¹⁸F]pitavastatin's hepatic uptake decreased (approximately 76%) with rifampicin co-administration in PET analysis. Because [¹⁸F]pitavastatin has lower clearance in rats than other previously reported OATP1B PET s, it holds the potential of an imaging tracer that has a higher sensitivity in monitoring hepatic OATP1B function's changes. Conclusion: Compared with the previously reported OATP imaging tracers, [¹⁸F]pitavastatin is more suitable for the sensitive detection of functional changes in OATP transporters. We believe that [¹⁸F]pitavastatin enables quantitative analysis of the hepatobiliary transport system for organic anion compounds.
Rights: © 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.
The full-text file will be made open to the public on 1 July 2020 in accordance with publisher's 'Terms and Conditions for Self-Archiving'.
This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
URI: http://hdl.handle.net/2433/243897
DOI(Published Version): 10.1016/j.nucmedbio.2019.08.001
PubMed ID: 31450072
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.